Analyst Price Target is $2.15
▼ -3.59% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Paratek Pharmaceuticals in the last 3 months. The average price target is $2.15, with a high forecast of $2.15 and a low forecast of $2.15. The average price target represents a -3.59% upside from the last price of $2.23.
Current Consensus is
Hold
The current consensus among 1 polled investment analysts is to hold stock in Paratek Pharmaceuticals. This Hold consensus rating has held steady for over two years.
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
Read More
